Suppr超能文献

一位 47 岁男性,因慢性肾衰竭服用碳酸镧片导致高磷血症,现出现部分性大肠梗阻急症。

A 47-Year-Old Man with Hyperphosphatemia Due to Chronic Renal Failure Treated with Lanthanum Carbonate Tablets Presenting Acutely with Partial Large Bowel Obstruction.

机构信息

Department of Gastroenterology, General Hospital of Central Theater Command, Wuhan, Hubei, China (mainland).

Department of Clinical Pharmacy, General Hospital of Central Theater Command, Wuhan, Hubei, China (mainland).

出版信息

Am J Case Rep. 2023 Nov 23;24:e942113. doi: 10.12659/AJCR.942113.

Abstract

BACKGROUND Hyperphosphatemia is a complication of chronic renal failure (CRF) due to reduction in the glomerular filtration rate. Lanthanum carbonate is a commonly used phosphate binder for patients with CRF and hyperphosphatemia, but has adverse effects if patients are not monitored. This report is of a 47-year-old man with hyperphosphatemia due to CRF treated with lanthanum carbonate tablets who presented acutely with partial large bowel obstruction. The incidence of lanthanum carbonate causing intestinal obstruction is rare, and few cases in the literature have described the course of the disease in detail. CASE REPORT A 47-year-old man diagnosed with diabetic nephropathy underwent hemodialysis treatment and was prescribed 0.5 g/day of chewable lanthanum carbonate tablets. After taking lanthanum carbonate for 5 months, the patient experienced symptoms of decreased bowel movements and exhaustion, which progressively worsened. Abdominal computed tomography (CT) revealed multiple hyperdensities in the large bowel, indicating the presence of lanthanum deposition. Lanthanum carbonate was promptly discontinued. After undergoing enema and catharsis treatment, the large bowel obstruction was relieved, and the hyperdensities in the abdominal CT disappeared. The colonoscopy and histologic examination revealed ulcerations and inflammatory changes in the large bowel mucosa. CONCLUSIONS This report highlights the rare association between the use of lanthanum carbonate tablets and intestinal obstruction. Healthcare providers should enhance their vigilance regarding lanthanum carbonate-induced serious gastrointestinal adverse reactions and actively seek to detect lanthanum deposition by abdominal CT or radiography (X-ray). After the occurrence of lanthanum deposition, drug withdrawal and promotion of defecation are primary treatment methods.

摘要

背景

高磷血症是慢性肾衰竭(CRF)的并发症,由于肾小球滤过率降低所致。碳酸镧是 CRF 和高磷血症患者常用的磷结合剂,但如果不进行监测,可能会产生不良反应。本报告介绍了 1 例因 CRF 接受碳酸镧片治疗而发生高磷血症的 47 岁男性患者,该患者突发部分大肠梗阻。碳酸镧引起肠梗阻的发生率较低,文献中很少有病例详细描述疾病过程。

病例报告

1 例 47 岁男性,诊断为糖尿病肾病,行血液透析治疗,处方 0.5 g/天的咀嚼碳酸镧片。服用碳酸镧 5 个月后,患者出现便秘和乏力症状,且逐渐加重。腹部计算机断层扫描(CT)显示大肠多处高密度影,提示镧沉积。立即停用碳酸镧。经灌肠和通便治疗后,大肠梗阻缓解,腹部 CT 高密度影消失。结肠镜和组织学检查显示大肠黏膜溃疡和炎症改变。

结论

本报告强调了碳酸镧片使用与肠梗阻之间罕见的关联。医疗保健提供者应提高对碳酸镧引起的严重胃肠道不良反应的警惕性,并积极通过腹部 CT 或 X 射线检查(X 射线)检测镧沉积。发生镧沉积后,停药和促进排便是主要的治疗方法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/07d5/11009886/f184f5e5fc6d/amjcaserep-24-e942113-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验